Infectious Diseases
Morbidity and mortality due to infectious diseases have been dramatically reduced by improved vaccination, which is the most cost-effective public health measure to prevent spread of disease (Lambert et al., 2005). Most vaccines are given by intramuscular injection, even though the muscle is not a highly immunogenic organ (Hutin et al., 2003, Hohlfeld and Engel, 1994). The skin, in contrast, is a much more attractive site for vaccination from an immunologic perspective, because of its many resident dendritic cells and efficient drainage to lymph nodes (Debenedictis et al., 2001, Kupper and Fuhlbrigge, 2004).
Improved immunogenicity compared to SC or IM
- direct delivery to key immune cells in the superficial skin layers
- enhanced immune response
- dose reduction of vaccine
- to lower production cost
- to increase the availability of the vaccine
Cold chain reduction with dry formulation in patch
- to get higher rates of working vaccines/ successful vaccination
- to lower the cost
Up to 7 times lower packaging volume compared to vials
- to lower the cost
- to pack more drugs in a backpack of a immunization healthworker to outreach more people in the field
Low device cost compared to syringe cost
- 10 Cent per vaccination (at average 40 vaccines per day)
- to increase the availability of the vaccine
No contamination through sharp waste
- to lower the risk of health care workers
- to lower cost in waste management
Reproducible compared to microneedles or ID (Mantoux technique)
- to get higher rates of well done vaccination
Easy and fast
- high throughput
- low training cost
Painless and needle free
- perfect for children and adult
For more information have a look at this publication
Two clinical trials are ongoing, preliminary results of Influenza study NCT02988739 are available.
